These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34745146)

  • 21. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
    Kissick HT; Sanda MG; Dunn LK; Arredouani MS
    PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
    Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
    Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8
    Xiang SD; Wilson KL; Goubier A; Heyerick A; Plebanski M
    Front Immunol; 2018; 9():2968. PubMed ID: 30631324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses.
    Karkada M; Weir GM; Quinton T; Sammatur L; MacDonald LD; Grant A; Liwski R; Juskevicius R; Sinnathamby G; Philip R; Mansour M
    J Immunother; 2010 Apr; 33(3):250-61. PubMed ID: 20445345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative TCR:pMHC Dissociation Rate Assessment by NTAmers Reveals Antimelanoma T Cell Repertoires Enriched for High Functional Competence.
    Gannon PO; Wieckowski S; Baumgaertner P; Hebeisen M; Allard M; Speiser DE; Rufer N
    J Immunol; 2015 Jul; 195(1):356-66. PubMed ID: 26002978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.
    Schnurr M; Chen Q; Shin A; Chen W; Toy T; Jenderek C; Green S; Miloradovic L; Drane D; Davis ID; Villadangos J; Shortman K; Maraskovsky E; Cebon J
    Blood; 2005 Mar; 105(6):2465-72. PubMed ID: 15546948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
    Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH
    Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma.
    Ly LV; Sluijter M; van der Burg SH; Jager MJ; van Hall T
    J Immunol; 2013 Jan; 190(1):489-96. PubMed ID: 23203930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
    Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S
    Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid assessment of recognition efficiency and functional capacity of antigen-specific T-cell responses.
    Kohrt HE; Shu CT; Stuge TB; Holmes SP; Weber J; Lee PP
    J Immunother; 2005; 28(4):297-305. PubMed ID: 16000947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a T-cell receptor multimer with high avidity for detecting a naturally presented tumor-associated antigen on osteosarcoma cells.
    Watanabe K; Tsukahara T; Toji S; Saitoh S; Hirohashi Y; Nakatsugawa M; Kubo T; Kanaseki T; Kameshima H; Terui T; Sato N; Torigoe T
    Cancer Sci; 2019 Jan; 110(1):40-51. PubMed ID: 30375705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy targeting tumor-associated antigen in a mouse model of head and neck cancer.
    Kono M; Wakisaka R; Komatsuda H; Hayashi R; Kumai T; Yamaki H; Sato R; Nagato T; Ohkuri T; Kosaka A; Ohara K; Kishibe K; Kobayashi H; Hayashi T; Takahara M
    Head Neck; 2024 Aug; 46(8):2056-2067. PubMed ID: 38390628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells.
    Assudani D; Cho HI; DeVito N; Bradley N; Celis E
    Cancer Res; 2008 Dec; 68(23):9892-9. PubMed ID: 19047170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extending antigen release from particulate vaccines results in enhanced antitumor immune response.
    Kapadia CH; Tian S; Perry JL; Sailer D; Christopher Luft J; DeSimone JM
    J Control Release; 2018 Jan; 269():393-404. PubMed ID: 29146244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination.
    Vence LM; Wang C; Pappu H; Anson RE; Patel TA; Miller P; Bassett R; Lizee G; Overwijk WW; Komanduri K; Benjamin C; Alvarado G; Patel SP; Kim K; Papadopoulos NE; Bedikian AY; Homsi J; Hwu WJ; Boyd R; Radvanyi L; Hwu P
    J Immunother; 2013 May; 36(4):276-86. PubMed ID: 23603862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clonotypic T cell receptor is a source of tumor-associated antigens in cutaneous T cell lymphoma.
    Berger CL; Longley J; Hanlon D; Girardi M; Edelson R
    Ann N Y Acad Sci; 2001 Sep; 941():106-22. PubMed ID: 11594564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice.
    Zhao X; Bose A; Komita H; Taylor JL; Chi N; Lowe DB; Okada H; Cao Y; Mukhopadhyay D; Cohen PA; Storkus WJ
    J Immunol; 2012 Feb; 188(4):1782-8. PubMed ID: 22246626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccine.
    Belnoue E; Mayol JF; Carboni S; Di Berardino Besson W; Dupuychaffray E; Nelde A; Stevanovic S; Santiago-Raber ML; Walker PR; Derouazi M
    JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31013258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peptides of tetraspanin oncoprotein CD151 trigger active immunity against primary tumour and experimental lung metastasis.
    Lin W; Liu J; Chen J; Li J; Qiu S; Ma J; Lin X; Zhang L; Wu J
    EBioMedicine; 2019 Nov; 49():133-144. PubMed ID: 31668880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
    Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
    Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.